新型口服生物制剂治疗炎症性肠病的研究进展  

Advances in Study on Novel Oral Biological Agents in Treatment of Inflammatory Bowel Disease

作　　者：周易[1] 沈骏[1] 冉志华[1] 

机构地区：[1]上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所,200001

出　　处：《胃肠病学》2017年第8期498-501,共4页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金项目(81470820;81670497)

摘　　要：生物制剂作为近二十年来新兴的治疗药物,对炎症性肠病(IBD)的疗效已得到肯定。然而,目前用于IBD治疗的生物制剂均需静脉滴注或皮下注射,部分制剂需要在严密观察下输注。因而,寻找一种安全、有效的口服生物制剂具有积极的临床意义。本文就近年新型口服生物制剂在IBD治疗中的研究进展作一综述。As a new therapy in past twenty years,biological agents have been approved for the treatment of inflammatory bowel disease（ IBD）. However,biological agents currently used for IBD treatment require intravenous or subcutaneous injections,and some require infusion under close observation. Therefore,it is of positive clinical significance to find a safe and effective oral biological agent. This article reviewed recent advances in study on novel oral biological agents in the treatment of IBD.

关 键 词：炎症性肠病 CROHN病 结肠炎 溃疡性 生物制剂 投药 口服 

分 类 号：R574[医药卫生—消化系统]